Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: bazedoxifene Clear all
Completed No phase listed Observational Results available

Study Evaluating Changes In Mammographic Breast Density

NCT00774267
View directory record Official record
Conditions
Osteoporosis
Interventions
BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 21, 2026, 5:44 AM EDT
Enrolling by invitation Phase 4 Interventional

Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee

NCT05059626
View directory record Official record
Conditions
Endometriosis
Interventions
simvastatin 10mg, Bazedoxifene 20/Estrogens,Con 0.45Mg Tb
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 21, 2026, 5:44 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Advancing Postmenopausal Preventive Therapy

NCT04103476
View directory record Official record
Conditions
Atherosclerosis, Cognitive Decline
Interventions
Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg, Placebo
Combination Product · Other
Lead sponsor
University of Southern California
Other
Eligibility
45 Years to 59 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women

NCT00465075
View directory record Official record
Conditions
Healthy
Interventions
Bazedoxifene/conjugated estrogens combination
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

NCT00242710
View directory record Official record
Conditions
Endometrial Hyperplasia, Osteoporosis
Interventions
Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Upland, California • Inverness, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women

NCT00706225
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene and conjugated estrogens
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2010 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation

NCT02729701
View directory record Official record
Conditions
Breast Cancer
Interventions
Duavee
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Up to 61 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Kansas City, Kansas • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 2 Interventional

The PROMISE Study: Duavee in Women With DCIS

NCT02694809
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Postmenopausal
Interventions
Conjugated Estrogens/Bazedoxifene, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
10
States / cities
Aurora, Colorado • Chicago, Illinois • Geneva, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms

NCT00479778
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene/conjugated estrogens
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 21, 2026, 5:44 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

NCT01634789
View directory record Official record
Conditions
Healthy
Interventions
bazedoxifene, bazedoxifene/conjugated estrogens
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 64 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 2 Interventional

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

NCT04002934
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Bazedoxifene Acetate
Drug
Lead sponsor
Riley Bove, MD
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 21, 2026, 5:44 AM EDT
Completed No phase listed Observational

Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density

NCT00418236
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 63 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
San Diego, California • Upland, California • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 21, 2026, 5:44 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

NCT04821141
View directory record Official record
Conditions
Risk Reduction, Breast Cancer
Interventions
Bazedoxifene and Conjugated Estrogens
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years to 64 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
6
States / cities
Duarte, California • San Francisco, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Premarin and Bazedoxifene Potential Interaction

NCT00745173
View directory record Official record
Conditions
Postmenopause
Interventions
Premarin
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2009 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause

NCT00234819
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
Phoenix, Arizona • Fort Myers, Florida • North Port Richey, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

NCT02710214
View directory record Official record
Conditions
Menopause, Multiple Sclerosis
Interventions
Tissue Selective Estrogen Complex, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 62 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers

NCT04821375
View directory record Official record
Conditions
Increased Risk for Development of Breast Cancer
Interventions
bazedoxifene plus conjugated estrogens
Drug
Lead sponsor
Carol Fabian, MD
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132
View directory record Official record
Conditions
Menopause, Osteoporosis
Interventions
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg, conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
143
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

NCT00238732
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)

NCT02237079
View directory record Official record
Conditions
Obesity, Glucose Homeostasis, Postmenopausal Symptoms
Interventions
Bazedoxifene/Conjugated Estrogens (BZA/CE), Placebo Oral Tablet
Drug
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
50 Years to 60 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women

NCT02100553
View directory record Official record
Conditions
Healthy
Interventions
CE/BZA, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

NCT00205777
View directory record Official record
Conditions
Osteoporosis
Interventions
Bazedoxifene Acetate, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
7,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
205
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 141 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Raising Insulin Sensitivity in Post Menopause

NCT02274571
View directory record Official record
Conditions
Menopause
Interventions
TSEC (Tissue-selective estrogen complexes), Placebo
Drug · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
50 Years to 60 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 21, 2026, 5:44 AM EDT
Terminated No phase listed Observational

Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene

NCT00847821
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg, Bazedoxifene 10 mg/CE 0.45 mg, Bazedoxifene 20 mg/CE 0.45 mg, Bazedoxifene 40 mg/CE 0.45 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2010 · Synced Oct 21, 2026, 5:44 AM EDT